or Try an Advanced Search...

    Treatment Of Cancer Stocks List

    Symbol Grade Name % Change
    EXEL B Exelixis, Inc. 2.24
    TGTX B TG Therapeutics, Inc. 1.51
    ACTU B Actuate Therapeutics, Inc. -0.22
    KPTI C Karyopharm Therapeutics Inc. 8.67
    ELEV D Elevation Oncology, Inc. -0.30
    ELTX D Elicio Therapeutics, Inc. -3.71
    INAB D IN8bio, Inc. -0.75
    RNA D Avidity Biosciences, Inc. 1.62
    NRIX D Nurix Therapeutics, Inc. -1.43
    CERO D CERo Therapeutics Holdings, Inc. -12.02
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Care Medical Instruments & Supplies Other Scientific & Technical Instruments
    Related Stock Lists: Cancer Biotechnology Biopharmaceutical Lymphoma Disease Life Sciences Solid Tumors Antibody Drug Conjugate Cell Therapy Clinical Medicine Hematological Malignancies Medicine Monoclonal Antibody Oncology Pharmaceutical Products Small Molecule Therapies Tyrosine Kinase Acute Leukemia Adoptive Cell Transfer Advanced Solid Tumors

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Cancer stocks.

    Symbol Grade Name Weight
    IDNA F iShares Genomics Immunology and Healthcare ETF 8.16
    PBE C PowerShares Dynamic Biotech & Genome 7.64
    BBP C BioShares Biotechnology Products Fund 5.16
    SURI C Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 5.13
    CNCR F Loncar Cancer Immunotherapy ETF 4.76
    View all Treatment Of Cancer ETFs...
    Compare ETFs
    Compare IDNA to CNCR Compare PBE to CNCR Compare SURI to CNCR

        Treatment Of Cancer Stocks Recent News

        Date Stock Title
        Nov 21 EXEL 3 Reasons Growth Investors Will Love Exelixis (EXEL)
        Nov 21 TGTX TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
        Nov 20 KPTI Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
        Nov 20 NRIX Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
        Nov 20 EXEL Zacks.com featured highlights Amazon, Maplebear, Exelixis and Doximity
        Nov 18 KPTI Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
        Nov 17 NRIX Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Care Medical Instruments & Supplies Other Scientific & Technical Instruments
        Related Stock Lists: Cancer Biotechnology Biopharmaceutical Lymphoma Disease Life Sciences Solid Tumors Antibody Drug Conjugate Cell Therapy Clinical Medicine Hematological Malignancies Medicine Monoclonal Antibody Oncology Pharmaceutical Products Small Molecule Therapies Tyrosine Kinase Acute Leukemia Adoptive Cell Transfer Advanced Solid Tumors
        Treatment Of Cancer

        Treatment of cancer depends on the type and stage of the cancer, as well as the patient's overall health and preferences. Treatment options may include surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and/or hormone therapy. In some cases, a combination of treatments may be used.

        Browse All Tags